Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
- PMID: 8040345
- PMCID: PMC296173
- DOI: 10.1172/JCI117412
Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
Abstract
Apolipoprotein E (apo E)-deficient mice are severely hypercholesterolemic and develop advanced atheromas independent of diet. The C57BL/6 strain differs from most inbred strains by having lower HDL concentrations and a high risk of developing early atherosclerotic lesions when fed an atherogenic diet. The relative HDL deficiency and atherosclerosis susceptibility of the C57BL/6 strain are corrected with the expression of a human apolipoprotein AI (apo AI) transgene in this genetic background. To examine if increases in apo AI and HDL are also effective in minimizing apo E deficiency--induced atherosclerosis, we introduced the human apo AI transgene into the hypercholesterolemic apo E knockout background. Similar elevations of total plasma cholesterol occurred in both the apo E knockout and apo E knockout mice also expressing the human apo AI transgene. The latter animals, however, also showed a two- to threefold increase in HDL and a sixfold decrease in susceptibility to atherosclerosis. This study demonstrates that elevating the concentration of apo AI reduces atherosclerosis in apo E deficient-mice and suggests that elevation of apo AI and HDL may prove to be a useful approach for treating unrelated causes of heightened atherosclerosis susceptibility.
Similar articles
-
Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.J Clin Invest. 1998 Jul 15;102(2):379-85. doi: 10.1172/JCI3038. J Clin Invest. 1998. PMID: 9664079 Free PMC article.
-
HDL deficiency in genetically engineered mice requires elevated LDL to accelerate atherogenesis.Arterioscler Thromb Vasc Biol. 1997 Sep;17(9):1725-9. doi: 10.1161/01.atv.17.9.1725. Arterioscler Thromb Vasc Biol. 1997. PMID: 9327769
-
Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100.J Clin Invest. 1997 Jul 1;100(1):180-8. doi: 10.1172/JCI119511. J Clin Invest. 1997. PMID: 9202070 Free PMC article.
-
[Value of transgenic mouse as model for the study of human lipoprotein metabolism].Ann Biol Clin (Paris). 1995;53(4):209-20. Ann Biol Clin (Paris). 1995. PMID: 7574108 Review. French.
-
Atheroprotective mechanisms of HDL.Atherosclerosis. 1999 Jun;144(2):285-301. doi: 10.1016/s0021-9150(99)00065-9. Atherosclerosis. 1999. PMID: 10407490 Review.
Cited by
-
High density lipoprotein, apolipoprotein A-I, and coronary artery disease.Mol Cell Biochem. 2000 Jun;209(1-2):131-44. doi: 10.1023/a:1007111830472. Mol Cell Biochem. 2000. PMID: 10942211 Review.
-
An apoA-I mimetic peptide increases LCAT activity in mice through increasing HDL concentration.Int J Biol Sci. 2009 Jul 28;5(5):489-99. doi: 10.7150/ijbs.5.489. Int J Biol Sci. 2009. PMID: 19680471 Free PMC article.
-
High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis.Curr Atheroscler Rep. 2000 Sep;2(5):363-72. doi: 10.1007/s11883-000-0074-4. Curr Atheroscler Rep. 2000. PMID: 11122767 Review.
-
Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production.J Physiol Pharmacol. 2010 Jun;61(3):309-16. J Physiol Pharmacol. 2010. PMID: 20610861 Free PMC article.
-
PPARalpha deficiency reduces insulin resistance and atherosclerosis in apoE-null mice.J Clin Invest. 2001 Apr;107(8):1025-34. doi: 10.1172/JCI11497. J Clin Invest. 2001. PMID: 11306606 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases